Abuse-Deterrent Dextroamphetamine Formulation for Cognitive Impairment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective treatments for cognitive impairment, particularly in COVID-19 survivors, as existing options are limited for conditions caused by COVID-19 and mechanical ventilation, and current treatments for these cases are inadequate.
Innovation Solution
An abuse-deterrent formulation of dextroamphetamine, combined with poloxamer 124, gellan gum, and polyoxyl stearate, administered once daily in a capsule form, is used to treat or alleviate symptoms of cognitive impairment, with a specific ratio of 40:30:30 for poloxamer 124:gellan gum:polyoxyl stearate, and a unit dose of dextroamphetamine ranging from 10 mg to 50 mg.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dextroamphetamine is formulated as an abuse-deterrent formulation with poloxamer 124, gellan gum, and polyoxyl stearate, then misuse prevention is improved, but formulation complexity increases
Solution Approach 1:
The patent applies composite materials by combining dextroamphetamine with multiple excipients (poloxamer 124, gellan gum, and polyoxyl stearate) in specific ratios to create an abuse-deterrent formulation. This composite approach provides misuse prevention through the complex matrix structure while maintaining controlled drug release, resolving the contradiction between reliability and complexity by integrating multiple functional components into a unified formulation system.
Solution Approach 2:
The patent employs parameter changes by optimizing the ratios of excipients (poloxamer 124:gellan gum:polyoxyl stearate at 40:30:30) and dextroamphetamine dosage (10-50 mg) to achieve both abuse deterrence and therapeutic efficacy. By systematically adjusting these parameters, the formulation achieves misuse prevention without excessive complexity, as the optimized ratios ensure proper drug release characteristics and structural integrity.
2Reliability
If an abuse-deterrent formulation is designed to prevent misuse, then reliability against misuse is improved, but ease of manufacture deteriorates
Solution Approach 1:
The patent simplifies manufacturing by establishing specific parameter ranges for excipient ratios (40:30:30) and drug dosage (10-50 mg), which provides clear formulation guidelines for production. These defined parameters reduce manufacturing complexity by eliminating the need for extensive optimization during production, while still achieving abuse deterrence through the formulated matrix structure and controlled release characteristics.
3Reliability
If dextroamphetamine is administered at higher doses to treat cognitive impairment, then therapeutic effect is improved, but risk of abuse and side effects increases
Solution Approach 1:
The patent optimizes the dextroamphetamine dosage parameter to 10-50 mg per unit, which provides therapeutic efficacy for cognitive impairment while reducing abuse risk through the abuse-deterrent formulation matrix. The controlled release characteristics of the formulation ensure steady drug delivery, preventing peak concentrations that could lead to abuse, while maintaining effective treatment levels for cognitive symptoms.
Solution Approach 2:
The abuse-deterrent matrix (poloxamer 124, gellan gum, and polyoxyl stearate) acts as an intermediary that controls drug release and reduces abuse potential. This matrix mediates between the therapeutic need for effective dextroamphetamine dosing and the harm reduction goal, allowing adequate therapeutic effect while preventing misuse through the formulation's physical and chemical barriers to abuse.
Data Source
AI summary
The present invention relates generally method of treating or alleviating cognitive impairment by administering an abuse-deterrent formulation containing dextroamphetamine sulfate.